BioLife has developed a novel oral peptide delivery technology that uses a dissolvable effervescent tablet format to protect peptide medicines during digestion. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept.
Newron Pharmaceuticals' evenamide has been shown to target the key site of schizophrenia pathology in the hippocampus, improving positive, negative, and cognitive symptoms. The study's findings suggest that evenamide could offer a novel therapeutic strategy capable of addressing schizophrenia-related dysfunction.
CLAIRITY BREAST is an FDA-authorized AI platform that analyzes mammogram images to predict five-year breast cancer risk. The platform was trained on millions of images and validated across over 77,000 mammograms, providing a more accurate risk assessment for women with diverse backgrounds.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Neflamapimod, a p38α kinase inhibitor, demonstrates reversible neurodegeneration in animal models and improves clinical endpoints associated with cholinergic neuronal function in patients with dementia with Lewy bodies. The findings support the initiation of a confirmatory Phase 2b clinical trial for neflamapimod.
Alphataxin, a small-molecule drug, has been shown to significantly suppress tumor growth in mouse models of kidney cancer, including those with lung metastasis. The treatment also increased the formation of CD4+ T cells, which is essential for the immune system's ability to kill tumor cells.
A live-cell screening strategy identified Kv7.2/7.3 as a key target for treating hyperexcitability-induced neurodegeneration in ALS patients. QurAlis' therapeutic candidate QRL-101 (QRA-244) shows promise in decreasing spinal and cortical motor neuron excitability.
Etrasimod demonstrated clinically meaningful improvements in both clinical signs of atopic dermatitis and patient reported outcomes. The treatment group achieved statistical significance in the percentage change in weekly peak pruritis, Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM).
OCU400, a novel gene therapy product candidate, demonstrates efficacy in rescuing photoreceptors from degeneration by resetting retinal homeostasis. The treatment has the potential to be broadly effective across genetically diverse IRDs, offering hope for millions of people worldwide affected by inherited retinal degenerations.
The Phase 2 randomized clinical trial confirmed the safety and well-tolerability of a single transplantation of autologous bone-marrow derived MSC-NTF cells (NurOwn) in participants with ALS. Key efficacy findings included stabilization of ALS disease progression, improvement in ALSFRS-R slope, and changes in CSF neurotrophic factors a...
Landos Biopharma has completed a $60 million Series B financing round to support global Phase 2 clinical trials of its lead product BT-11 for ulcerative colitis and Crohn's disease. The funding will also advance additional pipeline candidates, addressing an unmet clinical need for new therapies in inflammatory bowel disease.